VICTOZA Drug Patent Profile
✉ Email this page to a colleague
When do Victoza patents expire, and what generic alternatives are available?
Victoza is a drug marketed by Novo Nordisk Inc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred patent family members in twenty-nine countries.
The generic ingredient in VICTOZA is liraglutide. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the liraglutide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Victoza
A generic version of VICTOZA was approved as liraglutide by HIKMA on December 23rd, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VICTOZA?
- What are the global sales for VICTOZA?
- What is Average Wholesale Price for VICTOZA?
Summary for VICTOZA
International Patents: | 100 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 27 |
Clinical Trials: | 126 |
Patent Applications: | 2,997 |
Drug Prices: | Drug price information for VICTOZA |
Drug Sales Revenues: | Drug sales revenues for VICTOZA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VICTOZA |
What excipients (inactive ingredients) are in VICTOZA? | VICTOZA excipients list |
DailyMed Link: | VICTOZA at DailyMed |



DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VICTOZA
Generic Entry Date for VICTOZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VICTOZA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Chicago | Early Phase 1 |
Carmot Therapeutics, Inc. | Phase 1 |
Yale University | Phase 3 |
Pharmacology for VICTOZA
Drug Class | GLP-1 Receptor Agonist |
Mechanism of Action | Glucagon-like Peptide-1 (GLP-1) Agonists |
Paragraph IV (Patent) Challenges for VICTOZA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VICTOZA | Injection | liraglutide | 18 mg/3 mL prefilled syringe | 022341 | 1 | 2016-12-12 |
US Patents and Regulatory Information for VICTOZA
VICTOZA is protected by four US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VICTOZA is ⤷ Try for Free.
This potential generic entry date is based on patent 8,114,833.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | AP | RX | Yes | Yes | 8,114,833*PED | ⤷ Try for Free | Y | ⤷ Try for Free | ||
Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | AP | RX | Yes | Yes | 7,762,994*PED | ⤷ Try for Free | Y | ⤷ Try for Free | ||
Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | AP | RX | Yes | Yes | 9,265,893*PED | ⤷ Try for Free | Y | ⤷ Try for Free | ||
Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | AP | RX | Yes | Yes | 9,968,659*PED | ⤷ Try for Free | Y | ⤷ Try for Free | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VICTOZA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | 6,004,297 | ⤷ Try for Free |
Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | 7,235,627 | ⤷ Try for Free |
Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RE43834 | ⤷ Try for Free |
Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | 6,235,004 | ⤷ Try for Free |
Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | 6,458,924 | ⤷ Try for Free |
Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RE41956*PED | ⤷ Try for Free |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VICTOZA
See the table below for patents covering VICTOZA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Chile | 2018002515 | Liraglutida en afecciones cardiovasculares. | ⤷ Try for Free |
China | 1271086 | ⤷ Try for Free | |
European Patent Office | 1687019 | FORMULATIONS PEPTIDIQUES A BASE DE PROPYLENE GLYCOL OPTIMALES POUR LA PRODUCTION ET L'UTILISATION DANS DES DISPOSITIFS D'INJECTION (PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES) | ⤷ Try for Free |
Hungary | 0003920 | ⤷ Try for Free | |
Russian Federation | 2009132183 | НАЖИМНАЯ КНОПКА ДЛЯ ИНЪЕКЦИОННОГО УСТРОЙСТВА | ⤷ Try for Free |
World Intellectual Property Organization (WIPO) | 2005049061 | ⤷ Try for Free | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VICTOZA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0944648 | 09C0054 | France | ⤷ Try for Free | PRODUCT NAME: LIRAGLUTIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/529/001 DU 20090630; REGISTRATION NO/DATE AT EEC: EU/1/09/529/001 DU 20090630 |
2209800 | 122014000114 | Germany | ⤷ Try for Free | PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918 |
2209800 | 14C0085 | France | ⤷ Try for Free | PRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918 |
2209800 | C300698 | Netherlands | ⤷ Try for Free | PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918 |
0944648 | SPC/GB09/058 | United Kingdom | ⤷ Try for Free | PRODUCT NAME: LIRAGLUTIDE; REGISTERED: UK EU/1/09/529/001 20090630 |
2209800 | SPC/GB14/079 | United Kingdom | ⤷ Try for Free | PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF, AND LIRAGLUTIDE, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF; REGISTERED: CH 65041 20140912; UK EU/1/14/947 20140922 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for Victoza (Liraglutide)
More… ↓